Sagimet Biosciences Inc.(SGMT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SGMT Sagimet Biosciences Inc.

Post-Mkt 08-20 17:43:34 EDT

10.18

-0.40

-3.78%

盘后10.26

+0.08+0.79%

16:44 EDT

High10.64	Low10.15	Vol1.14M
Open10.48	D1 Closing10.58	Amplitude4.58%
Mkt Cap632.78M	Tradable Cap603.08M	Total Shares62.16M
T/O11.71M	T/O Rate1.92%	Tradable Shares59.24M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SGMT","market":"US","secType":"STK","nameCN":"Sagimet Biosciences Inc.","latestPrice":10.18,"timestamp":1787256000000,"preClose":10.58,"halted":0,"volume":1138733,"hourTrading":{"tag":"盘后","latestPrice":10.26,"preClose":10.18,"latestTime":"16:44 EDT","volume":3907,"amount":39800.171416,"timestamp":1787258668014,"change":0.08,"changeRate":0.007859,"amplitude":0.019646},"delay":0,"changeRate":-0.037807183364839354,"floatShares":59241840,"shares":62158653,"eps":-1.248952,"marketStatus":"Post-Mkt","change":-0.4,"latestTime":"08-20 17:43:34 EDT","open":10.48,"high":10.635,"low":10.15,"amount":11709370.524798,"amplitude":0.045841,"askPrice":10.49,"askSize":17,"bidPrice":9.9,"bidSize":40,"shortable":3,"etf":0,"ttmEps":-1.248952,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787270400000},"marketStatusCode":4,"adr":0,"listingDate":1689307200000,"exchange":"NASDAQ","adjPreClose":10.58,"preHourTrading":{"tag":"盘前","latestPrice":10.53,"preClose":10.58,"latestTime":"09:14 EDT","volume":1803,"amount":18985.786527,"timestamp":1787231661143,"change":-0.05,"changeRate":-0.004726,"amplitude":0.101134},"postHourTrading":{"tag":"盘后","latestPrice":10.26,"preClose":10.18,"latestTime":"16:44 EDT","volume":3907,"amount":39800.171416,"timestamp":1787258668014,"change":0.08,"changeRate":0.007859,"amplitude":0.019646},"volumeRatio":0.714471,"impliedVol":0.8281,"impliedVolPercentile":0.1036},"requestUrl":"/m/hq/s/SGMT/wiki","defaultTab":"wiki","newsList":[{"id":"2660432556","title":"Sagimet Biosciences Grants 260,700 Inducement Stock Options to New Hires","url":"https://stock-news.laohu8.com/highlight/detail?id=2660432556","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660432556?lang=en_us&edition=fundamental","pubTime":"2026-08-18 04:28","pubTimestamp":1786998504,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences grants 260,700 inducement stock options to new hiresSagimet Biosciences set inducement equity awards tied to three new hires, totaling 260,700 stock options for Series A common sha","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDL7TtRXQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BCDF","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00BN0W2W23.USD","BK4588","SG9999014005.SGD","BK4139","SG9999014021.USD","LU0314104364.USD","LU2095319765.USD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","LU2210150020.SGD","BK4585","SG9999014013.SGD","IE00BKPKM429.USD","LU2210149790.SGD","SG9999014039.USD","SGMT","NDAQ","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660043253","title":"Sagimet Biosciences Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2660043253","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660043253?lang=en_us&edition=fundamental","pubTime":"2026-08-18 04:28","pubTimestamp":1786998494,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nTUAB5GKRG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SGMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660508432","title":"Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2660508432","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660508432?lang=en_us&edition=fundamental","pubTime":"2026-08-18 04:28","pubTimestamp":1786998480,"startTime":"0","endTime":"0","summary":"FOSTER CITY, Calif., Aug.  17, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc.(Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabol","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/17/3346482/0/en/sagimet-biosciences-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCLG","BK4139","SGMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660048943","title":"Sagimet Biosciences price target raised to $56 from $49 at Canaccord","url":"https://stock-news.laohu8.com/highlight/detail?id=2660048943","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660048943?lang=en_us&edition=fundamental","pubTime":"2026-08-17 18:01","pubTimestamp":1786960911,"startTime":"0","endTime":"0","summary":"Canaccord raised the firm’s price target on Sagimet Biosciences (SGMT) to $56 from $49 and keeps a Buy rating on the shares. The firm said Sagimet ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-price-target-raised-to-56-from-49-at-canaccord-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sagimet-biosciences-price-target-raised-to-56-from-49-at-canaccord-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659156990","title":"Sagimet Wins FDA IND Clearance for Phase 3 Denifanstat Acne Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2659156990","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659156990?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:05","pubTimestamp":1786619153,"startTime":"0","endTime":"0","summary":"Sagimet wins FDA IND clearance for Phase 3 denifanstat acne trialSagimet won FDA IND clearance for a Phase 3 U.S. trial of denifanstat in moderate-to-severe acne.FDA issued a “Study May Proceed” lette","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL183G6l:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4112","BK4585","SGMT","BK4139","SG9999014039.USD","SG9999014005.SGD","LU2095319765.USD","BK4588","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","NDAQ","LU2210150020.SGD","LU2210149790.SGD","LU0314104364.USD","IE00BN0W2W23.USD","BCDF","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","SG9999014013.SGD","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659155728","title":"Sagimet Biosciences Receives FDA “Study May Proceed” Letter and Ind Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2659155728","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659155728?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:00","pubTimestamp":1786618802,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nTUA86HY5Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SGMT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659155720","title":"Sagimet Biosciences Inc.: Phase 3 Clinical Trial is on Track to Initiate in Second Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2659155720","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659155720?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:00","pubTimestamp":1786618802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nTUA86HY5Q:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SGMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659189329","title":"Sagimet Director George Kemble Disposes of 20,206 Common Shares Worth $201,160.97","url":"https://stock-news.laohu8.com/highlight/detail?id=2659189329","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659189329?lang=en_us&edition=fundamental","pubTime":"2026-08-13 07:41","pubTimestamp":1786578105,"startTime":"0","endTime":"0","summary":"Sagimet director George Kemble disposes of 20,206 common shares worth $201,160.97Sagimet Biosciences director George Kemble sold 20,206 shares of Series A Common Stock on Aug. 11, 2026 at USD 9.95.He ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL4DzCVC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"Sagimet Director George Kemble Disposes of 20,206 Common Shares Worth $201,160.97","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659909489","title":"Sagimet Biosciences Price Target Raised to $56.00/Share from $49.00 by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2659909489","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659909489?lang=en_us&edition=fundamental","pubTime":"2026-08-13 00:05","pubTimestamp":1786550700,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SGMT/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658974411","title":"Edward Nash Initiates Buy on Sagimet, Citing De-Risked Late-Stage Acne Program and Significant U.S. Market Opportunity","url":"https://stock-news.laohu8.com/highlight/detail?id=2658974411","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658974411?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:35","pubTimestamp":1786534549,"startTime":"0","endTime":"0","summary":"Canaccord Genuity analyst Edward Nash maintained a Buy rating on Sagimet Biosciences, Inc. Class A yesterday and set a price target of $49.00. Edwa...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/edward-nash-initiates-buy-on-sagimet-citing-de-risked-late-stage-acne-program-and-significant-u-s-market-opportunity-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/edward-nash-initiates-buy-on-sagimet-citing-de-risked-late-stage-acne-program-and-significant-u-s-market-opportunity-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SGMT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658276289","title":"U.S. Research Roundup-Cardinal Health, Lumentum Holdings, Public Storage","url":"https://stock-news.laohu8.com/highlight/detail?id=2658276289","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658276289?lang=en_us&edition=fundamental","pubTime":"2026-08-12 16:07","pubTimestamp":1786522040,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Cardinal Health, Lumentum Holdings, Public StorageAug 12 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, inclu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL4N4490GI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JBIO","ARKG","GAP","CVS","SR","TGT","EGGY","LOW","COAG","ACM","AUAU","BLCK","CANC","HD","FLUT","RSPS","ACVA","BBIO","LAZR","MNST","CAH","CUBE","CRCL","LITE","NEM","LEGN","BCAX","LPTH","MAA","RPD","LENZ","REZ","GDX","CAVA","FXU","MRCY","PNW","JAZZ","HLIO","LBRX","NTRA","PSA","AMBQ","SGMT","MDLN","CRWV","ANF","ODDZ","EXR","TXG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658948040","title":"Inhibikase Q2 Net Loss Widens on Higher R&D, SG&A Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2658948040","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658948040?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:10","pubTimestamp":1786479023,"startTime":"0","endTime":"0","summary":"Inhibikase Q2 net loss widens on higher R&D, SG&A costsOverviewU.S. clinical-stage pharma's Q2 net loss widened yr/yr on higher R&D and SG&A costsCompany raised $50 mln in July via share sale to RA Ca","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL1N4480Y8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IKT","BK4007","SGMT","LBRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658917818","title":"Sagimet Making 'Good Progress' in Bringing Denifanstat to US Patients, Wedbush Securities Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2658917818","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658917818?lang=en_us&edition=fundamental","pubTime":"2026-08-12 01:54","pubTimestamp":1786470873,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences  is making \"good progress\" in advancing denifanstat as a treatment for moderate to severe acne for the US market, Wedbush Securities said in a note Tuesday.The investment firm said positive data from studies conducted in China suggest limited clinical risk for the experimental therapy, which is expected to enter phase 3 testing in H2 after regulatory clearance.The company expects fast patient enrollment in the phase 3 study, with topline data possible by the end of 2027 or in early 2028, according to the note.Wedbush said Sagimet ended Q2 with $257.6 million in cash after raising $175 million in April, with its cash runway expected to extend through 2028 and beyond the anticipated denifanstat phase 3 readout.The firm said recent investor discussions reinforced the view that Sagimet remains \"deeply undervalued\" and continues to offer significant upside despite recent share gains.Wedbush Securities has an outperform rating on Sagimet Biosciences, with a price target o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PRGS","BK4139","LU2065732104.USD","SGMT","BK4097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658791274","title":"Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), Legend Biotech (LEGN) and Sagimet Biosciences, Inc. Class A (SGMT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658791274","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658791274?lang=en_us&edition=fundamental","pubTime":"2026-08-12 01:40","pubTimestamp":1786470008,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Immunic (IMUX), Legend Biotech (LEGN) and Sagimet Bi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-immunic-imux-legend-biotech-legn-and-sagimet-biosciences-inc-class-a-sgmt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-immunic-imux-legend-biotech-legn-and-sagimet-biosciences-inc-class-a-sgmt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","BK4581","HCSG","LU0029874061.USD","LU0128526141.USD","XLV","BK4139","BK4588","BK4585","MEMS","IMUX","MEDI","CANC","XBI","LEGN","LABU","SGMT","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658899053","title":"Sagimet Highlights Q2 Results and Dermatology Focus Shift","url":"https://stock-news.laohu8.com/highlight/detail?id=2658899053","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658899053?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:59","pubTimestamp":1786449598,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences, Inc. Class A ( ($SGMT) ) just unveiled an announcement. Sagimet Biosciences reported its second-quarter 2026 results on August...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/sagimet-highlights-q2-results-and-dermatology-focus-shift?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/sagimet-highlights-q2-results-and-dermatology-focus-shift?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SGMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658997978","title":"Sagimet Biosciences Q2 EPS $(0.26) Misses $(0.25) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2658997978","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658997978?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:46","pubTimestamp":1786448794,"startTime":"0","endTime":"0","summary":"Sagimet Biosciences (NASDAQ:SGMT) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.25) by 4 percent. This is a 18.75 percent increase over losses of $(0.32) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61104568/sagimet-biosciences-q2-eps-0-26-misses-0-25-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658997810","title":"Sagimet Net Loss Widens to $14 Million in Q2 FY26; R&D Expense Climbs to $11.54 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658997810","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658997810?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:31","pubTimestamp":1786447891,"startTime":"0","endTime":"0","summary":"Sagimet net loss widens to $14 million in Q2 FY26; R&D expense climbs to $11.54 millionSagimet posted a net loss of USD 14 million for Q2 2026, widening from USD 10.39 million a year earlier.Research ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL8rbXf0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","BK4139","IE00BN0W2T93.GBP","LU0314104364.USD","NDAQ","IE00BN0W2W23.USD","IE00B64PRP62.GBP","BK4585","BK4112","LU2210149790.SGD","SG9999014039.USD","IE00BN0W2V16.EUR","BCDF","SG9999014013.SGD","SGMT","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","SG9999014021.USD","BK4588","LU2095319765.USD","IE00BKPKM429.USD","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658997957","title":"Sagimet Biosciences Q2 EPS USD -0.26","url":"https://stock-news.laohu8.com/highlight/detail?id=2658997957","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658997957?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:30","pubTimestamp":1786447801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nPLXN5943T:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SGMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658992080","title":"Press Release: Sagimet Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2658992080","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658992080?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:30","pubTimestamp":1786447800,"startTime":"0","endTime":"0","summary":"advance denifanstat in moderate to severe acne for the U.S., prioritizing. -- Equity financing: In April 2026, the Company completed an underwritten. equity financing resulting in $175.0 million of gross proceeds, before. deducting underwriting discounts and commissions and other offering. -- Russell Index inclusion: Sagimet was added to the broad-market Russell. 3000 Index and small-cap Russell 2000 Index effective June 29,-- TVB-3567: A first-in-human Phase 1 clinical trial of FASN inhibitor. -- KOL event: On April 30, 2026, the Company hosted a Key Opinion Leader. event with Julie Harper, MD, founding Director and past President of. the American Acne and Rosacea Society, discussing the acne treatment. landscape and Sagimet's planned Phase 3 clinical trial. A recording of. the event is accessible at this link.Publications and Presentations-- Data showing that Sagimet's FASN inhibitors reduced de novo lipid levels. in human sebocytes were presented at the 83rd Society for Investigativ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT","MEDX","R","BK4022","BK4232","HYLG","IDNA","NVIB","BK1145","BK4139","00511","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656255880","title":"Sagimet Biosciences to Participate in the Canaccord Genuity 46th Annual Growth Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2656255880","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656255880?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:00","pubTimestamp":1785841200,"startTime":"0","endTime":"0","summary":"FOSTER CITY, Calif., Aug.  04, 2026  (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc.(Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabo","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/04/3338136/0/en/Sagimet-Biosciences-to-Participate-in-the-Canaccord-Genuity-46th-Annual-Growth-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sagimet.com","stockEarnings":[{"period":"1week","weight":0.1267},{"period":"1month","weight":0.4777},{"period":"3month","weight":0.5114},{"period":"6month","weight":0.9887},{"period":"1year","weight":0.5311},{"period":"ytd","weight":0.7872}],"compareEarnings":[{"period":"1week","weight":-0.0044},{"period":"1month","weight":0.0363},{"period":"3month","weight":0.0355},{"period":"6month","weight":0.1155},{"period":"1year","weight":0.202},{"period":"ytd","weight":0.1278}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.228208},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.167334},{"month":3,"riseRate":0,"avgChangeRate":-0.107746},{"month":4,"riseRate":0.666667,"avgChangeRate":0.104894},{"month":5,"riseRate":0.666667,"avgChangeRate":0.101166},{"month":6,"riseRate":0.666667,"avgChangeRate":0.282829},{"month":7,"riseRate":0.333333,"avgChangeRate":0.014223},{"month":8,"riseRate":0.25,"avgChangeRate":0.006573},{"month":9,"riseRate":0,"avgChangeRate":-0.152908},{"month":10,"riseRate":0.666667,"avgChangeRate":0.172366},{"month":11,"riseRate":0.666667,"avgChangeRate":-0.001337},{"month":12,"riseRate":0.333333,"avgChangeRate":0.009885}],"exchange":"NASDAQ","name":"Sagimet Biosciences Inc.","nameEN":"Sagimet Biosciences Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Sagimet Biosciences Inc.(SGMT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Sagimet Biosciences Inc.(SGMT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Sagimet Biosciences Inc.,SGMT,Sagimet Biosciences Inc.股票,Sagimet Biosciences Inc.股票老虎,Sagimet Biosciences Inc.股票老虎国际,Sagimet Biosciences Inc.行情,Sagimet Biosciences Inc.股票行情,Sagimet Biosciences Inc.股价,Sagimet Biosciences Inc.股市,Sagimet Biosciences Inc.股票价格,Sagimet Biosciences Inc.股票交易,Sagimet Biosciences Inc.股票购买,Sagimet Biosciences Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Sagimet Biosciences Inc.(SGMT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Sagimet Biosciences Inc.(SGMT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}